Drug intelligence / Profile preview

AGX9902

Development stage: Preclinical
Lead developer: Forum Health
Modality: Small Molecules
Administration: Oral

Overview

AGX9902 is a generic oral liquid drug candidate developed by Agenix Pharmaceuticals. It is part of a portfolio of niche generic oral liquid dosage forms (designated AGX9901 through AGX9905) that the company is developing for the pharmaceutical market. As of the available information, the specific active pharmaceutical ingredient (API) and therapeutic indications for AGX9902 have not been publicly disclosed. The program has progressed through R&D and CDMO development stages, with target Abbreviated New Drug Application (ANDA) filing dates originally projected between late 2020 and 2021.

Beyond the preview

Go deeper on AGX9902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGX9902.

Explore the full profile